# LEMAITRE VASCULAR, INC. (LMAT) · Edgar & Edgarette company card

> Lemaitre Vascular (LMAT) grew revenue 13.5% in FY2025 to $250 million, operating margin 27.2% against a 1.2% median for surgical & medical instruments & apparatus, equity 63.9% of assets, and dividend per share up 14 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1158895 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/LMAT) · [JSON](https://www.pops4.com/boards/company/LMAT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $250M |
| Revenue growth, 1 year | 13.5% |
| Revenue growth per year | 12.8% |
| Operating margin | 27.2% (prior year 23.8%) |
| Net margin | 23.1% |
| Operating cash flow | $81M |
| Capital spending | $7M |
| Free cash flow | $74M |
| Cash | $28M |
| Long-term debt | — |
| Total assets | $616M |
| Total equity | $394M |
| Equity ÷ assets | 63.9% |
| Return on equity | 14.7% |
| Dividend per share | $0.8 |
| Dividend years rising | 14 |

## Readings, computed from those figures

- Altman Z: 8.18 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -2.65 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow now · steady, with strong cash arriving today

## Edgarette's reading

Exposure: revenue $249.6M (FY2025). Experience: revenue up 13.5% on the year, up 12.8% a year over 4 years; operating margin 27.2%, up from 23.8%. Soundness: equity 63.9% of assets, return on equity 14.7%, payout 31.4% of profit, dividend per share up 14 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $244.9M and $320.6M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $228.7M to $344.1M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 27.2% against a 1.2% median; growth 13.5% against 11.6%.

Range logged 2026-10-16, receipt fea567c70aeb5adf, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-15 ([filing](https://www.sec.gov/Archives/edgar/data/1158895/000119312526422885/0001193125-26-422885-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1158895/000119312526448437/0001193125-26-448437-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1158895/000119312526447467/0001193125-26-447467-index.htm)
- 8-K · filed 2026-10-15 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1158895/000119312526422885/0001193125-26-422885-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1158895/000119312526333762/0001193125-26-333762-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1158895/000119312526332982/0001193125-26-332982-index.htm)
- 8-K · filed 2026-06-05 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1158895/000119312526257978/0001193125-26-257978-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001158895.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1158895

## Cite

POPS4, Edgar & Edgarette: LEMAITRE VASCULAR, INC. (LMAT) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/LMAT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

